These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33333040)

  • 1. Development and validation of a noninvasive clinical scoring system to predict significant fibrosis in patients with nonalcoholic fatty liver disease.
    Jin W; Xu Y; Zhu W; Xia Z; Wu J
    Clin Chim Acta; 2021 Mar; 514():48-53. PubMed ID: 33333040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease.
    Yang M; Jiang L; Wang Y; Li X; Zou Z; Han T; Nan Y; Lu F; Zhao J
    J Gastrointestin Liver Dis; 2019 Sep; 28(3):289-296. PubMed ID: 31517325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis.
    Tavaglione F; Jamialahmadi O; De Vincentis A; Qadri S; Mowlaei ME; Mancina RM; Ciociola E; Carotti S; Perrone G; Bruni V; Gallo IF; Tuccinardi D; Bianco C; Prati D; Manfrini S; Pozzilli P; Picardi A; Caricato M; Yki-Järvinen H; Valenti L; Vespasiani-Gentilucci U; Romeo S
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1523-1532.e1. PubMed ID: 35421583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified thresholds for fibrosis risk scores in nonalcoholic fatty liver disease are necessary in the obese.
    Ooi GJ; Burton PR; Doyle L; Wentworth JM; Bhathal PS; Sikaris K; Cowley MA; Roberts SK; Kemp W; O'Brien PE; Brown WA
    Obes Surg; 2017 Jan; 27(1):115-125. PubMed ID: 27220852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease.
    Ruffillo G; Fassio E; Alvarez E; Landeira G; Longo C; Domínguez N; Gualano G
    J Hepatol; 2011 Jan; 54(1):160-3. PubMed ID: 20934232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram.
    Zhou YJ; Ye FZ; Li YY; Pan XY; Chen YX; Wu XX; Xiong JJ; Liu WY; Xu SH; Chen YP; Zheng MH
    United European Gastroenterol J; 2019 Oct; 7(8):1124-1134. PubMed ID: 31662869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD.
    Feng G; Zheng KI; Li YY; Rios RS; Zhu PW; Pan XY; Li G; Ma HL; Tang LJ; Byrne CD; Targher G; He N; Mi M; Chen YP; Zheng MH
    J Hepatobiliary Pancreat Sci; 2021 Jul; 28(7):593-603. PubMed ID: 33908180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population.
    Pérez-Gutiérrez OZ; Hernández-Rocha C; Candia-Balboa RA; Arrese MA; Benítez C; Brizuela-Alcántara DC; Méndez-Sánchez N; Uribe M; Chávez-Tapia NC
    Ann Hepatol; 2013; 12(3):416-24. PubMed ID: 23619258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease.
    Staufer K; Halilbasic E; Spindelboeck W; Eilenberg M; Prager G; Stadlbauer V; Posch A; Munda P; Marculescu R; Obermayer-Pietsch B; Stift J; Lackner C; Trauner M; Stauber RE
    United European Gastroenterol J; 2019 Oct; 7(8):1113-1123. PubMed ID: 31662868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical and laboratory-based nomogram for predicting nonalcoholic fatty liver disease in non-diabetic adults: a cross-sectional study.
    Qian Y; Sun B; Zhang Y; Zhang M; Jiao X; Lai L; Yang W
    Ann Palliat Med; 2022 Jul; 11(7):2349-2359. PubMed ID: 35542976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.
    Cen C; Wang W; Yu S; Tang X; Liu J; Liu Y; Zhou L; Yu J; Zheng S
    Hepatol Int; 2020 Sep; 14(5):808-816. PubMed ID: 32572817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of noninvasive scores for the diagnosis of advanced liver fibrosis in morbidly obese with nonalcoholic fatty liver disease.
    de Carli MA; de Carli LA; Correa MB; Junqueira G; Tovo CV; Coral GP
    Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):420-425. PubMed ID: 31464779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of P2/MS and other noninvasive fibrosis scoring systems in the Korean population with nonalcoholic fatty liver disease.
    Yu SJ; Kim DH; Lee JH; Chung GE; Yim JY; Park MJ; Kim YJ; Yoon JH; Jang JJ; Lee HS
    Korean J Gastroenterol; 2011 Jan; 57(1):19-27. PubMed ID: 21258197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.
    Angulo P; Hui JM; Marchesini G; Bugianesi E; George J; Farrell GC; Enders F; Saksena S; Burt AD; Bida JP; Lindor K; Sanderson SO; Lenzi M; Adams LA; Kench J; Therneau TM; Day CP
    Hepatology; 2007 Apr; 45(4):846-54. PubMed ID: 17393509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.